View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Deals Analysis
June 21, 2019

Pharma industry M&A deals in May 2019 total $9.4bn globally

Total pharma industry M&A deals in May 2019 worth $9.4bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 129.1% over the previous month and a drop of 37.2% when compared with the last 12-month average, which stood at $14.97bn.

Comparing deals value in different regions of the globe, held the top position, with total announced deals in the period worth $5.3bn. At the country level, topped the list in terms of deal value at $5.3bn.

In terms of volumes, North America emerged as the top region for pharma industry M&A deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of M&A deals activity in May 2019 was the US with 20 deals, followed by the UK with two and Denmark with two.

In 2019, as of the end of May 2019, pharma M&A deals worth $149.78bn were announced globally, marking a decrease of 6.9% year on year.

Pharma industry M&A deals in May 2019: Top deals

The top five pharma industry M&A deals accounted for 94.4% of the overall value during May 2019.

The combined value of the top five pharma industry M&A deals stood at $8.88bn, against the overall value of $9.4bn recorded for the month. The top announced pharma industry M&A deal tracked by GlobalData in May 2019 was Novartis ‘ $5.3bn asset transaction with Takeda Pharmaceutical .

In second place was the $2.2bn acquisition of Peloton Therapeutics by Merck &Inc and in third place was Pfizer’s $810m acquisition of Therachon .

The $400m acquisition of Abide Therapeutics by H. Lundbeck and Amgen ‘s acquisition of Nuevolution for $167m held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

 

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology